Processing
DECODED™ online newsletter
How to facilitate your research on the 2019 Novel Coronavirus (SARS-CoV-2)
Webinar summary: Learn about IDT’s high-quality line of genomic reagents that can be used to facilitate your research of COVID-19, caused by the novel coronavirus, 2019-nCoV (officially named SARS-CoV-2).
- Ribosomal RNA depletion from bacteria for RNA-seq using CRISPR-associated Cas9
- Successful genome editing in CD34+ hematopoietic stem and progenitor cells (HSPCs)
- CRISPR-mediated deletion of glucocorticoid receptor protects viral-specific T cells against lymphocytotoxic effects of glucocorticoid treatment
- A mutant A.s. Cas12a (Cpf1) for CRISPR genome editing shows broad temperature tolerance and high specificity and activity, with site-to-site reliability rivaling S.p. Cas9
- Guaranteed knockdown of RNA in loss-of-function studies
- Enzyme-linked DNA aptamer assay provides advantages over standard immunoassays
Need help designing assays?
IDT experts have published a new application guide for gene expression experiments
Get the free guideDeep, uniform coverage is now more cost-effective
xGen Predesigned Gene Capture Pools
See new tiered pricingxGen Exome Research Panel
Best-in-class exome sequencing solution, endorsed by Illumina
Find out more